Norio Itokawa
Nippon Medical School(JP)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Hepatitis C virus research, Hepatitis B Virus Studies, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis(2019)158 cited
- → Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis(2018)130 cited
- → Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis(2022)128 cited
- → Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population(2022)126 cited
- → Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease(2016)105 cited
- → Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib(2020)95 cited
- → Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase(2023)84 cited
- → Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma(2019)83 cited
- → Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan(2019)80 cited
- → Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma(2020)79 cited